A Phase 4 interventional study of Antioxidants + Clomiphene Citrate and Antioxidants + FSH in Oligoasthenoteratozoospermia and Male Infertility, sponsored by Hamad Medical Corporation. Not yet recruiting at 1 site in Qatar. Open to male participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Hamad Medical Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective randomized controlled trial will compare three treatment approaches for men with idiopathic oligoasthenoteratozoospermia (OAT), a condition characterized by abnormalities in sperm count, movement, and shape without an identified cause. Participants will be randomly assigned in a 1:1:1 ratio to receive antioxidant therapy alone, antioxidant therapy plus clomiphene citrate, or antioxidant therapy plus follicle-stimulating hormone (FSH) for 6 months.
The study will evaluate whether adding clomiphene citrate or FSH to antioxidant therapy improves semen parameters compared with antioxidant therapy alone. The main outcomes will include changes in sperm concentration, motility, and morphology. The study will also assess sperm function, hormonal changes, treatment adherence, and adverse events.
64 studies on the registry are indexed under Oligospermia; 17 are open to participants now.
This study's planned enrollment of 360 is above the median of 65 across 46 interventional studies indexed under Oligospermia.
Browse Oligospermia studies →Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive antioxidant therapy consisting of vitamin C 1000 mg/day, vitamin E 400 IU/day, L-carnitine, and zinc 25 mg/day for 6 months.
Drug: Antioxidants + Clomiphene Citrate · Drug: Antioxidants + FSH
Participants will receive the same antioxidant regimen plus clomiphene citrate 50 mg orally every other day for 6 months.
Drug: Antioxidants + FSH · Drug: Antioxidants Alone
Participants will receive the same antioxidant regimen plus FSH 150 IU administered subcutaneously three times weekly for 6 months.
Drug: Antioxidants + Clomiphene Citrate · Drug: Antioxidants Alone
Drug pages: Antioxidants · Clomiphene
Participants will receive the same antioxidant regimen as the active comparator arm plus clomiphene citrate 50 mg orally every other day for 6 months.
Also known as: Clomiphene Citrate, Antioxidants
Drug pages: Antioxidants · Follicle Stimulating Hormone
Participants will receive the same antioxidant regimen plus FSH 150 IU administered subcutaneously three times weekly for 6 months.
Also known as: Antioxidants, follicle-stimulating hormone
Participants will receive antioxidant therapy consisting of vitamin C 1000 mg/day, vitamin E 400 IU/day, L-carnitine, and zinc 25 mg/day for 6 months
Change in Sperm Concentration
Change in sperm concentration, measured in million sperm/mL, from baseline to 6 months after initiation of treatment.
Time frame: Baseline and 6 months
Change in Sperm Motility
Change in sperm motility, measured as the percentage of motile sperm, from baseline to 6 months after initiation of treatment.
Time frame: Baseline and 6 months
Change in Sperm Morphology
Change in normal sperm morphology from baseline to 6 months after initiation of treatment.
Time frame: from baseline to 6 months
Change in oxidative stress / oxidation-reduction potential
Change in seminal oxidative stress measured by oxidation-reduction potential (ORP).
Time frame: Baseline and 6 months
Change in sperm DNA fragmentation
Change in sperm DNA fragmentation, measured using the study's specified sperm function testing method.
Time frame: Baseline and 6 months
Change in follicle-stimulating hormone
Change in serum FSH concentration from baseline to 6 months.
Time frame: Baseline to 6 months
Change in Luteinizing Hormone
Change in serum luteinizing hormone (LH) concentration from baseline to 6 months.
Time frame: From baseline to 6 months.
Change in Testosterone
Change in serum testosterone concentration from baseline to 6 months.
Time frame: from baseline to 6 months
Change in Estradiol
Change in serum estradiol concentration from baseline to 6 months.
Time frame: baseline to 6 months
Treatment Tolerability and Adverse Events
Assessment of treatment tolerability and occurrence of adverse events during the treatment period.
Time frame: From treatment initiation through 6 months
Medication Adherence
Assessment of adherence to the assigned study treatment during the treatment period.
Time frame: From treatment initiation through 6 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Antioxidants · Clomiphene · Follicle Stimulating Hormone